Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OGA | O60502 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19588730 | 0.84 | OGA (0.38) | OGATSHRALOX15 | |
| SCHEMBL15369268 | 0.70 | OGA (0.43) | OGA | |
| SCHEMBL20229509 | 0.69 | OGA (0.45) | OGATSHR | |
| SCHEMBL1130665 | 0.69 | OGA (0.45) | OGATSHR | |
| SCHEMBL23813680 | 0.69 | OGA (0.39) | OGATSHR | |
| SCHEMBL23127812 | 0.69 | OGA (0.39) | OGATSHR | |
| SCHEMBL10819153 | 0.67 | OGA (0.43) | OGATSHR | |
| SCHEMBL25503323 | 0.66 | OGA (0.53) | OGATSHR | |
| SCHEMBL13341455 | 0.65 | OGA (0.44) | OGATSHR | |
| SCHEMBL18082004 | 0.65 | OGA (0.44) | OGATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11319526-B2 | Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation | SEAGEN INC. (US) | 2022-05-03 | — | — | US | disclosed |
| US-20190276796-A1 | METHODS AND COMPOSITIONS FOR MAKING ANTIBODIES AND ANTIBODY DERIVATIVES WITH REDUCED CORE FUCOSYLATION | SEAGEN INC. | 2019-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190276796-A1 | METHODS AND COMPOSITIONS FOR MAKING ANTIBODIES AND ANTIBODY DERIVATIVES WITH REDUCED CORE FUCOSYLATION | FUT5, FUCA2, FCGR3B | OGA 85/4885TSHR 1665/4885ALOX15 3275/4885 |
| US-11319526-B2 | Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation | FUT5, FUCA2, FCGR3B | OGA 85/4885TSHR 1665/4885ALOX15 3275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.